Loading... Please wait...

Our Newsletter

Abiraterone | P450 CYP17 inhibitor

  • Abiraterone.jpg
  • Abiraterone, 400x400px, png
Catalog #:

Product Description

Abiraterone is a potent steroidal inhibitor against cytochrome P450 17alpha-hydroxylase-17,20-lyase (CYP17) with an IC50 at 4 nM. It was approved by the FDA in April 2011 to treat castration-resistant prostate cancer. A phase I/II clinical trial evaluating abiraterone acetate in advanced breast cancer patients are also underway. In preclinical studies, abiraterone has demonstrated the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes.

Technical information:

Chemical Formula:   C24H31NO
CAS #:   154229-19-3
Molecular Weight:   349.51
Purity:   >98%
Apperance:   White solid
Chemical Name:   (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-
Solubility:   Up to 50 mM in DMSO

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Attard G et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742-8.
2. Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563-71.

Other Information:

Product Specification (pdf)
MSDS (pdf)

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the Abiraterone | P450 CYP17 inhibitor to your wish list.

You Recently Viewed...